Recent news on Retavase

PDL BioPharma Raises 2007 Outlook  -  May 2, 2007
Forbes,In 2006, the company earned 5 cents per share, excluding a $72.1 million charge for the acquisition of heart-attack drug Retavase.

Third Point Urges PDL BioPharma to Cut Costs  -  Mar 25, 2007
Drug Newswire (press release),...you made what we consider to be an ill- conceived purchase of ESP Pharma for $500M to gain access to products Cardene IV, Retavase and Busulfex.

PDL BioPharma: Third Point Raises Stake, Urges Company to Cut Costs  -  Mar 6, 2007
Seeking Alpha,...you made what we consider to bean ill-conceived purchase of ESP Pharma for $500M to gain access to productsCardene IV, Retavase and Busulfex.

PDL Biopharma Sees Bigger 4th-Quarter Loss on Hefty Charge for ...  -  Feb 21, 2007
Canadian Business,Excluding a $72.1 million charge for the heart-attack drug Retavase, which the company acquired last year from ESP Pharma, PDL Biopharma said it earned 5

PDL BioPharma Announces Fourth Quarter and Full Year 2006 ...  -  Feb 21, 2007
Earthtimes.orgThe 2006 GAAP net losses for the fourth quarter and the full year included a $72.1 million asset impairment charge related to the company's Retavase(R)

PDL BioPharma's Q4 loss widens  -  Feb 22, 2007
Charlotte Business Journal,The results included a $72.1 million impairment charge accounting for reduced net cash flow expectations for Retavase, the company's blood clot drug.

PDL Biopharma's Fair Q4: Fool by Numbers  -  Feb 22, 2007
Motley FoolNet loss has widened, primarily due to asset impairment charges to the tune of $72.1 million related to the company's Retavase product.

UPDATE 1-PDL Biopharma fourth-quarter net loss widens  -  Feb 21, 2007
Reuters...fourth-quarter net loss widened due to higher costs, including a $72.1 million charge related to reduced cash flow expectations for heart drug Retavase.

Heart attack drug back on track after manufacturing issues  -  Feb 14, 2007
OutSourcing-Pharma.com,During the first six months of 2006, PDL's contract manufacturer for Retavase experienced excess costs related to manufacturing difficulties as a result of

Diosynth Biotechnology Announces Extension of Commercial Supply ...  -  Feb 7, 2007
dBusinessNews Triangle (press release),TRIANGLE -- Diosynth Biotechnology signed an extension of its exclusive agreement with PDL BioPharma, Inc. for the commercial manufacture of Retavase®

Diosynth Biotechnology Announces Extension of Commercial Supply ...  -  Feb 7, 2007
Business Wire (press release),Retavase is indicated for use in the management of acute myocardial infarction (AMI) in adults for the improvement of ventricular function following AMI,

Stocks to Watch: Abercrombie & Fitch, Apple, PDL BioPharma Toll ...  -  Feb 22, 2007
Minyanville.com,The results included a $72.1 million asset impairment charge related to Retavase. Excluding one-time items, the biopharmaceutical company posted a per-share

Stocks to Watch, Feb. 22: Whole Foods, H&R Block, Intuit  -  Feb 21, 2007
FOX NewsThe results included a $72.1 million asset impairment charge related to Retavase. Excluding one-time items, the Fremont, Calif.

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional